ERBB2 and lung carcinoma: Given that HER2 IHC 3+ or HER2 amplification by FISH is very rare in lung cancers, clinical trials evaluating the activity of trastuzumab in lung cancers with lower levels of HER2 IHC positivity have been negative [126,127].